An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients With Select Solid Tumors.

This study is testing a new oral medication called NEO212 to see if it is safe and effective at treating certain brain tumors and cancers that have spread to the brain. Researchers want to find the best dose and understand how well the drug works on its own or when combined with other existing cancer treatments.

This trial is for adults aged 18 and older who have been diagnosed with specific types of brain tumors or solid tumors that have spread to the brain. You must be in a stable condition regarding other medications and have recovered from the side effects of any previous cancer treatments.

Participants will take the study drug, NEO212, by mouth, either alone or in combination with other standard cancer therapies like immunotherapy or chemotherapy. Throughout the study, doctors will closely monitor your health, track how the cancer responds to the treatment, and record any side effects to ensure your safety.

The study is currently recruiting patients at medical centers in Beverly Hills, Glendale, and Los Angeles, California. It is divided into three phases to gradually learn the most effective and safe way to use the drug.